ALX Oncology Q3 net loss widens to $35.3M; secures $100M loan facility, extends cash runway to mid-2025

ALX ONCOLOGY HOLDINGS INC

2022-Q3 EPS reported -$2.28

GAAP net loss $35.3M ($0.87/diluted share) vs $24.6M ($0.61) in Q3 2021; non-GAAP loss $29.1M vs $20.4M.
Cash, equivalents, investments $293.1M; $100M term loan facility ($10M drawn) extends runway to mid-2025.
R&D expenses $29.4M (up 62% YoY) on increased clinical trial costs; G&A $7.3M (up 14%).
Initial Phase 1 ASPEN-05 AML data showed no MTD, full CD47 occupancy, anti-leukemic activity; ASH poster Dec 12, 2022.
New clinical trial arms: I-SPY-P1 for HER2 breast cancer (evorpacept + ENHERTU); Phase 2 CRC trial first patient dosed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

ALX ONCOLOGY HOLDINGS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-023194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.